Literature DB >> 19359262

Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus.

J G Hanly1, M B Urowitz, L Su, S C Bae, C Gordon, D J Wallace, A Clarke, S Bernatsky, D Isenberg, A Rahman, G S Alarcón, D D Gladman, P R Fortin, J Sanchez-Guerrero, J Romero-Diaz, J T Merrill, E Ginzler, I N Bruce, K Steinsson, M Khamashta, M Petri, S Manzi, M A Dooley, R Ramsey-Goldman, R Van Vollenhoven, O Nived, G Sturfelt, C Aranow, K Kalunian, M Ramos-Casals, A Zoma, J Douglas, K Thompson, V Farewell.   

Abstract

OBJECTIVES: To determine the frequency, accrual, attribution and outcome of neuropsychiatric (NP) events and impact on quality of life over 3 years in a large inception cohort of patients with systemic lupus erythematosus (SLE).
METHODS: The study was conducted by the Systemic Lupus International Collaborating Clinics. Patients were enrolled within 15 months of SLE diagnosis. NP events were identified using the American College of Rheumatology case definitions, and decision rules were derived to determine the proportion of NP disease attributable to SLE. The outcome of NP events was recorded and patient-perceived impact determined by the SF-36.
RESULTS: 1206 patients (89.6% female) with a mean (+/-SD) age of 34.5+/-13.2 years were included in the study. The mean disease duration at enrollment was 5.4+/-4.2 months. Over a mean follow-up of 1.9+/-1.2 years, 486/1206 (40.3%) patients had > or =1 NP events, which were attributed to SLE in 13.0-23.6% of patients using two a priori decision rules. The frequency of individual NP events varied from 47.1% (headache) to 0% (myasthenia gravis). The outcome was significantly better for those NP events attributed to SLE, especially if they occurred within 1.5 years of the diagnosis of SLE. Patients with NP events, regardless of attribution, had significantly lower summary scores for both mental and physical health over the study.
CONCLUSIONS: NP events in patients with SLE are of variable frequency, most commonly present early in the disease course and adversely impact patients' quality of life over time. Events attributed to non-SLE causes are more common than those due to SLE, although the latter have a more favourable outcome.

Entities:  

Mesh:

Year:  2009        PMID: 19359262      PMCID: PMC2929162          DOI: 10.1136/ard.2008.106351

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  36 in total

1.  Cognitive impairment in systemic lupus erythematosus: a follow-up study.

Authors:  S Carlomagno; S Migliaresi; L Ambrosone; M Sannino; G Sanges; G Di Iorio
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

2.  Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus.

Authors:  F B Karassa; J P Ioannidis; K A Boki; G Touloumi; M I Argyropoulou; K A Strigaris; H M Moutsopoulos
Journal:  Am J Med       Date:  2000-12-01       Impact factor: 4.965

3.  Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation.

Authors:  H Ainiala; A Hietaharju; J Loukkola; J Peltola; M Korpela; R Metsänoja; A Auvinen
Journal:  Arthritis Rheum       Date:  2001-10

4.  Systemic Lupus International Collaborating Group--onwards and upwards?

Authors:  D Isenberg; R Ramsey-Goldman
Journal:  Lupus       Date:  2006       Impact factor: 2.911

5.  Lost-to-follow-up study in systemic lupus erythematosus (SLE).

Authors:  D D Gladman; D R Koh; M B Urowitz; V T Farewell
Journal:  Lupus       Date:  2000       Impact factor: 2.911

6.  Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades.

Authors:  K E Moss; Y Ioannou; S M Sultan; I Haq; D A Isenberg
Journal:  Ann Rheum Dis       Date:  2002-05       Impact factor: 19.103

7.  Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.

Authors:  Mikiko Tokunaga; Kazuyoshi Saito; Daisuke Kawabata; Yoshitaka Imura; Takao Fujii; Shingo Nakayamada; Shizuyo Tsujimura; Masao Nawata; Shigeru Iwata; Taeko Azuma; Tsuneyo Mimori; Yoshiya Tanaka
Journal:  Ann Rheum Dis       Date:  2006-11-15       Impact factor: 19.103

8.  Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.

Authors:  John G Hanly; Grace McCurdy; Lisa Fougere; Jo-Anne Douglas; Kara Thompson
Journal:  J Rheumatol       Date:  2004-11       Impact factor: 4.666

9.  Systemic lupus erythematosus in a multiethnic U.S. cohort (LUMINA) XXXI: factors associated with patients being lost to follow-up.

Authors:  A M Bertoli; M Fernández; J Calvo-Alén; L M Vilá; M L Sanchez; J D Reveille; G S Alarcón
Journal:  Lupus       Date:  2006       Impact factor: 2.911

10.  Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study.

Authors:  J G Hanly; M B Urowitz; J Sanchez-Guerrero; S C Bae; C Gordon; D J Wallace; D Isenberg; G S Alarcón; A Clarke; S Bernatsky; J T Merrill; M Petri; M A Dooley; D Gladman; P R Fortin; K Steinsson; I Bruce; S Manzi; M Khamashta; A Zoma; C Aranow; E Ginzler; R Van Vollenhoven; J Font; G Sturfelt; O Nived; R Ramsey-Goldman; K Kalunian; J Douglas; K Thompson; V Farewell
Journal:  Arthritis Rheum       Date:  2007-01
View more
  76 in total

Review 1.  Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations.

Authors:  George K Bertsias; Dimitrios T Boumpas
Journal:  Nat Rev Rheumatol       Date:  2010-05-11       Impact factor: 20.543

Review 2.  A model for lupus brain disease.

Authors:  Betty Diamond; Bruce T Volpe
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

3.  Libman-Sacks endocarditis and embolic cerebrovascular disease.

Authors:  Carlos A Roldan; Wilmer L Sibbitt; Clifford R Qualls; Rex E Jung; Ernest R Greene; Charles M Gasparovic; Reyaad A Hayek; Gerald A Charlton; Kendall Crookston
Journal:  JACC Cardiovasc Imaging       Date:  2013-09

Review 4.  Cognitive Impairment in SLE: Mechanisms and Therapeutic Approaches.

Authors:  Aida Zarfeshani; Kaitlin R Carroll; Bruce T Volpe; Betty Diamond
Journal:  Curr Rheumatol Rep       Date:  2021-03-29       Impact factor: 4.592

5.  Cardiovascular and disease-related predictors of depression in systemic lupus erythematosus.

Authors:  Laura J Julian; Chris Tonner; Ed Yelin; Jinoos Yazdany; Laura Trupin; Lindsey A Criswell; Patricia P Katz
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-04       Impact factor: 4.794

6.  Attribution in the assessment of nervous system disease in SLE.

Authors:  John G Hanly
Journal:  Rheumatology (Oxford)       Date:  2014-12-05       Impact factor: 7.580

7.  [Neurological manifestations in connective tissue disease].

Authors:  L Harms; F Hiepe
Journal:  Z Rheumatol       Date:  2012-09       Impact factor: 1.372

Review 8.  Immunotherapies for Neurological Manifestations in the Context of Systemic Autoimmunity.

Authors:  Eleni I Kampylafka; Harry Alexopoulos; Marinos C Dalakas; Athanasios G Tzioufas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

9.  Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors.

Authors:  Julius Birnbaum; Clifton O Bingham
Journal:  Semin Arthritis Rheum       Date:  2013-10-30       Impact factor: 5.532

Review 10.  [Overcoming disease in systemic lupus erythematosus].

Authors:  M Schneider; M Haupt
Journal:  Z Rheumatol       Date:  2015-09       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.